Nanotechnology and the FDA: What are the scientific and regulatory considerations for products containing nanomaterials?

Nanotechnology Law and Business

Volumn 3, Issue 3, 2006, Pages 339-349

  Sadrieh, Nakissa ^a,b   Espandiari, Parvaneh ^b,c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b Food and Drug Administrations   (United States)

^c Office of Biotechnology Products   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DELIVERY; DRUG EVALUATION; MARKETED PRODUCTS; REGULATORY CONSIDERATIONS;

DRUG PRODUCTS; FOOD PRODUCTS; LAWS AND LEGISLATION; NANOSTRUCTURED MATERIALS; REGULATORY COMPLIANCE; RESEARCH AND DEVELOPMENT MANAGEMENT;

NANOTECHNOLOGY;

EID: 33750313627     PISSN: 15462080     EISSN: 15462080     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (34)

1. John P. Swann, History of the FDA, THE HISTORICAL GUIDE TO AMERICAN GOVERNMENT (George Kurian ed. 1998), available at http://www.fda.gov/oc/history/ historyoffda/fulltext.html (last visited July 14, 2006).
2. The Impact of Nanotechnology in Drug Discovery, Global Developments, Market Analysis and Future Prospects, NANOMARKETS.NET (Mar.7, 2005), http://www.nanomarkets.net/products/prod_detail.cfm?prod=6&id=199 (last visited July 14, 2006);
3. Nano Drug Delivery, The Impact of Nanotechnology in Drug Delivery: Global Developments, NANOMARKETS.NET (Mar. 21, 2005), http://www.nanomarkets.net/ products/prod_detail.cfm?prod=4&id=198 (last visited July 14, 2006);
4. S. S. Feng, Nanoparticles of Biodegradable Polymers for New-Concept Chemotherapy, 1 EXPERT REV. MED. DEVICES 115, 115-25 (2004);
5. M. Sato & T. J. Webster, Nanobiotechnology: Implications for the Future of Nanotechnology in Orthopedic Applications, 1 EXPERT REV. MED. DEVICES 105 (2004).
6. FOOD & DRUG ADMIN, (hereinafter "FDA"), INNOVATION OR STAGNATION: CHALLENGE AND OPPORTUNITY ON THE CRITICAL PATH TO NEW MEDICAL PRODUCTS (Mar. 2004), http://www.fda.gov/oc/initiatives/criticalpath/whitepaper. html (last visited July 14, 2006)
7. NAT'L NANOTECH. INITIATIVE (hereinafter "NNI"), What is Nanotechnology?, NANO.GOV (Apr. 15, 2004), http://www.nano.gov/html/facts/ whatIsNano.html (last visited July 14, 2006).
8. EUROPEAN SCIENCE FOUNDATION, NANOMEDICINE: AN ESF MEDICAL RESEARCH COUNCILS (EMRC) FORWARD LOOK REPORT (2005), http://www.esf.org/publication/214/ Nanomedicine.pdf (last visited July 14, 2006)
9. Nanotechnology Regulation, SCITECH RESOURCES.GOV (Aug. 13, 2003), http://www.scitechresources.gov/Results/show_result.php?rec=3284 (last visited July 14, 2006)
10. FDA, Overview of the Office of Combination Products, FDA.GOV, http://www.fda.gov/oc/combination/overview.html (last visited July 14, 2006).
11. Id.
12. Id.
13. FDA, FDA and Nanotechnology Products, FDA.GOV, http://www.fda.gov/ nanotechnology/faqs.html (last visited July 14, 2006).
14. Id.
15. See http://www.fda.gov/OHRMS/DOCKETS/98fr/05-16527.htm.
16. Id.
17. See FDA, Information for FDA-Regulated Industry, FDA.GOV, http://www.fda.gov/oc/industry/default.htm (last visited July 14, 2006).
18. R. A. Femia & R. E. Goyette, The Science of Megestrol Acetate Delivery: Potential to Improve Outcomes in Cachexia, 19 BIODRUGS. 179, 179-87 (2005);
19. J. Hu et al., Nanoparticle Engineering Processes for Enhancing the Dissolution Rates of Poorly Water Soluble Drugs, 30 DRUG DEV. IND. PHARM. 233 (2004);
20. E. Merisko-Liversidge et al., Nanosizing: a Formulation Approach for Poorly-Water-Soluble Compounds, 18 EUR. J. PHARM. SCI. 113, 113-20 (2003).
21. S. S. Feng, Nanoparticles of Biodegradable Polymers for New-Concept Chemotherapy, 1 EXPERT REV. MED. DEVICES 115, 115-25 (2004);
22. S. Gelperina et al., The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis, 172 AM. J. RESPIR. CRIT. CARE MED. 1487, 1487-90 (2005);
23. S. M. Moghimi et al., Nanomedicine: Current Status and Future Prospects, 19 FASEB J. 311, 311-30 (2005).
24. Mary C. Till, Michele M. Simkin & Stephen Maebius, Nanotech Meets the FDA: A Success Story about the First Nanoparticulate Drugs Approved by the FDA, 2 NANOTECH. L. & Bus. 163 (2005).
25. C. M. Sayes et al., The Differential Cytotoxicity of Water-Soluble Fullerenes, 4 NANO LETTERS 1881, 1881-87 (2004);
26. M. El-Sayed et al., Transepithelial Transport or Poly(amidoamine) Dendrimers Across Caco-2 Cell Monolayers, 81 J. CONTROL. RELEASE 355, 355-65 (2002);
27. R. Jevprasesphant et al., The Influence of Surface Modification on the Cytotoxicity of PAMAM Dendrimers, 18 INT. J. PHARMACEUT. 252, 263-66 (2003);
28. C. Lemarchand et al., Influence of Polysaccharide Coating on the Interactions of Nanoparticles with Biological Systems, 27 BIOMATERIALS 108, 108-18 (2006);
29. C. Kirchner et al., Cytotoxicity of Colloidal CdSe and CdSe/ZnS Nanoparticles, 5 NANO LETTERS 331, 331-38 (2005);
30. M. F. Neerman et al., In Vitro and In Vivo Evaluation of a Melamine Dendrimer as a Vehicle for Drug Delivery, 281 INT. J. PHARMACEUT. 129, 129-32 (2004);
31. S. Nigavekar et al., 3H Dendrimer Nanoparticle Organ/Tumor Distribution, 21 PHARMACEUT. RES. 476, 476-83 (2004);
32. N. Malik et al., Relationship between Structure and Biocompatibility In Vitro, and Preliminary Studies on the Biodistribution of 1251-Labeled Polyamidoamine Dendrimers In Vivo, 65 J. CONTROL. RELEASE. 133, 133-48 (2000);
33. J. C. Roberts et al., Preliminary Biological Evaluation of Polyamidoamine (PAMAM) Starburst Dendrimers, 30 J. BIOMED. MATER. RES. 53, 53-65 (1996);
34. R. Hardman, A Toxicological Review of Quantum Dots: Toxicity Depends on Physiochemical and Environmental Factors, 114 ENVT'L. HEALTH PERSPECT. 165, 165-72 (2006).